Drugs / Seltorexant
Trials 34 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 124 trials | ||||||
| Phase 1 | NCT05236868 | Feb → Mar 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05106153 | Dec 2021 → May 2023 | substance abuse | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04951609 | Sep 2021 → Apr 2024 | major depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04960124 | Aug → Nov 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04616677 | Mar 2021 → Oct 2022 | impaired renal function disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04553042 | Sep → Dec 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04451187 | Jul 2020 → Mar 2023 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03796026 | Jan → Jun 2019 | obstructive sleep apnea syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03682380 | Oct 2018 → Aug 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03494907 | Apr → Aug 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03438461 | Feb → May 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03374475 | Jan 2018 → Apr 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03249402 | Aug → Nov 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03025022 | Jan → Feb 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02837692 | Jun 2016 → Sep 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02661893 | Jan → Feb 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02578472 | Nov 2015 → Feb 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02617810 | Nov 2015 → Feb 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02555124 | Sep → Oct 2015 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT02476058 | Jun 2015 → Jan 2016 | major depressive disorder | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02475161 | Jun → Jul 2015 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02455856 | May → Jun 2015 | — | Janssen Cilag N.V./S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02230878 | May → Nov 2014 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02067299 | Feb → Dec 2014 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05307692 | May 2022 → Nov 2023 | Alzheimer disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03321526 | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03375203 | Nov 2017 → Apr 2019 | insomnia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03227224 | Aug 2017 → Jan 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02464046 | Jul → Dec 2015 | insomnia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07573176 | Apr 2026 → Aug 2028 expected | major depressive disorder | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06559306 | Jul 2024 → Dec 2026 expected | major depressive disorder | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT04533529 | Sep 2020 → Apr 2023 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04513912 | Sep 2020 → Oct 2023 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04532749 | Sep 2020 → May 2022 | major depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seltorexant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06559306 ↗ |
| Known as | JNJ-42847922 | “Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the treatment of adjunctive treatment of MDD...” NCT04951609 ↗22“A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and...” NCT03438461 ↗ “Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS.” NCT04532749 ↗ “The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).” NCT02476058 ↗ “Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R)” NCT04513912 ↗ |
| Known as | MIN-202 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3597971 ↗ |
| Action | Inhibit | “Seltorexant is a potent and selective antagonist of the orexin-2 receptor” PMID 29848147 ↗ May 20181“Orexin receptor 2 antagonist” CHEMBL3597971 ↗ |
| Modality | Small molecule | — CHEMBL3597971 ↗ |
| Route | Oral | “orally on Day 1” NCT02067299 ↗ |
| Target | HCRTR2 | “Orexin receptor 2 antagonist” CHEMBL3597971 ↗ |